Peter Caravan

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Peter Caravan sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 2 currently recruiting early-phase tilt upper quartile by trial count

Peter Caravan: 3 sponsored US clinical trials, 2 recruiting.

Peter Caravan sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Fibrosis, with 1 trials.

Upper-quartile sponsor footprint

Peter Caravan sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Peter Caravan pipeline

2 recruiting of 3 indexed (67% open).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Pulmonary Fibrosis (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Peter Caravan: open-pipeline peers nationwide

Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Peter Caravan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Peter Caravan10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAbbisko Therapeutics CoABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery Alliance
Peter Caravan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Peter Caravan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

What to do with this Peter Caravan page

3 registered trials is a research-attention snapshot, not an endorsement of Peter Caravan or any single study.

  • 2 of Peter Caravan's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pulmonary Fibrosis is the condition Peter Caravan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Fibrosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Peter Caravan pipeline card: 3 registered trials from official public datasets.Report a data error.